Oncolytic virotherapy: potentially a game-changing tumor treatment
A two-center phase I trial published in the New England Journal of Medicine shows safety and feasibility of locally administered oncolytic herpes simplex virus-1 virus plus 5 Gy radiation for progressive pediatric high-grade gliomas. Patients seemed to have an unusually good clinical course and show...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
14 June 2021
|
| In: |
Cancer cell
Year: 2021, Volume: 39, Issue: 6, Pages: 753-755 |
| ISSN: | 1878-3686 |
| DOI: | 10.1016/j.ccell.2021.05.014 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ccell.2021.05.014 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1535610821002804 
|
| Author Notes: | Tobias Kessler and Wolfgang Wick |
| Summary: | A two-center phase I trial published in the New England Journal of Medicine shows safety and feasibility of locally administered oncolytic herpes simplex virus-1 virus plus 5 Gy radiation for progressive pediatric high-grade gliomas. Patients seemed to have an unusually good clinical course and showed immune activation in post-treatment tissues. |
|---|---|
| Item Description: | Gesehen am 29.09.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1878-3686 |
| DOI: | 10.1016/j.ccell.2021.05.014 |